Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

BACC Bay Tocilizumab Trial
 
NCT04356937
RCTtocilizumab placeboCOVID 19 all comerslow
161/81 inconclusive
  • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).